PT1350109E - Marcador para patologias inflamatórias - Google Patents

Marcador para patologias inflamatórias Download PDF

Info

Publication number
PT1350109E
PT1350109E PT02707438T PT02707438T PT1350109E PT 1350109 E PT1350109 E PT 1350109E PT 02707438 T PT02707438 T PT 02707438T PT 02707438 T PT02707438 T PT 02707438T PT 1350109 E PT1350109 E PT 1350109E
Authority
PT
Portugal
Prior art keywords
marker
inflammatory conditions
pregnancy
plasma protein
acute coronary
Prior art date
Application number
PT02707438T
Other languages
English (en)
Inventor
Robert S Schwartz
Cheryl A Conover
Antonio Bayes-Genis
David R Holmes Jr
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation filed Critical Mayo Foundation
Publication of PT1350109E publication Critical patent/PT1350109E/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Rehabilitation Therapy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Nuclear Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT02707438T 2001-01-12 2002-01-11 Marcador para patologias inflamatórias PT1350109E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/760,376 US6500630B2 (en) 2001-01-12 2001-01-12 Marker for inflammatory conditions

Publications (1)

Publication Number Publication Date
PT1350109E true PT1350109E (pt) 2009-06-30

Family

ID=25058918

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02707438T PT1350109E (pt) 2001-01-12 2002-01-11 Marcador para patologias inflamatórias

Country Status (11)

Country Link
US (9) US6500630B2 (pt)
EP (2) EP2081026A1 (pt)
JP (3) JP4338972B2 (pt)
AT (1) ATE431551T1 (pt)
AU (1) AU2002241845B2 (pt)
CA (1) CA2434512C (pt)
DE (1) DE60232303D1 (pt)
DK (1) DK1350109T3 (pt)
ES (1) ES2324767T3 (pt)
PT (1) PT1350109E (pt)
WO (1) WO2002056015A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032953A2 (en) * 2000-10-20 2002-04-25 Como Biotech Aps Pregnancy-associated plasma protein-a2 (papp-a2)
US6500630B2 (en) * 2001-01-12 2002-12-31 Mayo Foundation For Medical Education And Research Marker for inflammatory conditions
DE60200248T2 (de) * 2002-08-01 2005-01-27 Mtm Laboratories Ag Verfahren für Lösung-basierte Diagnose
EP1962096B1 (de) * 2002-11-16 2012-07-18 Siemens Healthcare Diagnostics Products GmbH SCD40L, PAPP-A und plazentaler-Wachstumsfaktor (PIGF) als biochemische Markerkombination bei kardiovaskulären Erkrankungen
EP1530047A1 (en) * 2003-11-07 2005-05-11 Roche Diagnostics GmbH Proximal markers of arterial thrombosis and inflammation for risk stratification of coronary heart disease
SI1882946T1 (sl) * 2003-12-23 2010-06-30 Hoffmann La Roche Postopek za ugotavljanje revmatoidnega artritisa z merjenjem anti CCP in interlevkina
CN1934449A (zh) * 2004-01-28 2007-03-21 图尔库大学 用于诊断急性冠状动脉综合征的改进的方法
US7608458B2 (en) * 2004-02-05 2009-10-27 Medtronic, Inc. Identifying patients at risk for life threatening arrhythmias
CA2554836A1 (en) * 2004-02-05 2005-08-25 Medtronic, Inc. Methods and apparatus for identifying patients at risk for life threatening arrhythmias
US8335652B2 (en) * 2004-06-23 2012-12-18 Yougene Corp. Self-improving identification method
US20050287574A1 (en) * 2004-06-23 2005-12-29 Medtronic, Inc. Genetic diagnostic method for SCD risk stratification
US8027791B2 (en) * 2004-06-23 2011-09-27 Medtronic, Inc. Self-improving classification system
CN101268369A (zh) * 2005-06-29 2008-09-17 儒勒斯贝斯特医药有限公司 诊断急性冠状动脉综合症的方法和试剂盒
WO2007059332A2 (en) 2005-11-17 2007-05-24 Biogen Idec Ma Inc. Platelet aggregation assays
US20100310461A1 (en) * 2007-04-18 2010-12-09 Biochromix Pharma Ab Binding of pathological forms of proteins using conjugated polyelectrolytes
US20100310462A1 (en) * 2007-04-18 2010-12-09 Biochromix Ab Binding of pathological forms of proteins using conjugated polyelectrolytes
EP2017351B1 (en) * 2007-07-20 2010-10-27 Université de Liège Combined method for the sequential measurement of (1) the enzymatically active fraction and (2) the total amount of an enzyme
US20110143956A1 (en) * 2007-11-14 2011-06-16 Medtronic, Inc. Diagnostic Kits and Methods for SCD or SCA Therapy Selection
EP2222877A4 (en) * 2007-11-14 2011-10-12 Medtronic Inc GENETIC MARKERS FOR SCD OR SCA THERAPY SELECTION
US8130095B2 (en) 2008-08-27 2012-03-06 The Invention Science Fund I, Llc Health-related signaling via wearable items
US8125331B2 (en) 2008-08-27 2012-02-28 The Invention Science Fund I, Llc Health-related signaling via wearable items
US20100056873A1 (en) * 2008-08-27 2010-03-04 Allen Paul G Health-related signaling via wearable items
US8094009B2 (en) 2008-08-27 2012-01-10 The Invention Science Fund I, Llc Health-related signaling via wearable items
US8284046B2 (en) 2008-08-27 2012-10-09 The Invention Science Fund I, Llc Health-related signaling via wearable items
US20100081928A1 (en) * 2008-09-29 2010-04-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Histological Facilitation systems and methods
EP2430184A2 (en) * 2009-05-12 2012-03-21 Medtronic, Inc. Sca risk stratification by predicting patient response to anti-arrhythmics
FI20095733A0 (fi) 2009-06-29 2009-06-29 Hytest Oy IGFBP-4-fragmenttien määrittäminen diagnostisena menetelmänä
WO2011033034A1 (en) * 2009-09-17 2011-03-24 Roche Diagnostics Gmbh Multimarker panel for left ventricular hypertrophy
FI20115367A0 (fi) 2011-04-15 2011-04-15 Hytest Oy Menetelmä sydän- ja verisuonitapahtumien määrittämiseksi käyttämällä IGFBP-fragmentteja
US20150080738A1 (en) * 2011-08-16 2015-03-19 The General Hospital Corporation Apparatus, method, and computer-accessible medium for determining antigen immunoreactivity in tissue
CN106460062A (zh) 2014-05-05 2017-02-22 美敦力公司 用于scd、crt、crt‑d或sca治疗识别和/或选择的方法和组合物
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
RU2646490C1 (ru) * 2016-09-16 2018-03-05 Гюзелия Хатыбулловна Каюмова Способ прогнозирования летальности у пациентов с инфарктом миокарда
US11519024B2 (en) * 2017-08-04 2022-12-06 Billiontoone, Inc. Homologous genomic regions for characterization associated with biological targets
WO2019028462A1 (en) 2017-08-04 2019-02-07 Billiontoone, Inc. TARGET-ASSOCIATED MOLECULES FOR CHARACTERIZATION ASSOCIATED WITH BIOLOGICAL TARGETS
KR102109850B1 (ko) * 2017-08-21 2020-05-13 한양대학교 산학협력단 염증의 유무 예측을 위한 바이오마커
IL320862A (en) 2022-11-15 2025-07-01 Calico Life Sciences Llc Anti-PAPP-A antibodies and methods of using them

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US525641A (en) * 1894-09-04 Weather-strip
US5039521A (en) * 1989-01-11 1991-08-13 Hyal Pharmaceutical Corporation Immune cell proliferation inhibitors
US5324502A (en) * 1992-04-02 1994-06-28 Purdue Research Foundation Radiopharmaceuticals for imaging the heart
ES2140469T3 (es) * 1992-10-14 2000-03-01 Nycomed Imaging As Composiciones y metodos terapeuticos y de diagnostico por obtencion de imagenes.
WO1994021686A1 (en) * 1993-03-19 1994-09-29 Northern Sydney Area Health Service Papp-a, its immunodetection and uses
ATE458499T1 (de) * 1995-06-07 2010-03-15 Immunomedics Inc Verbesserte abgabe von diagnostischen und therapeutischen stoffen an einem zielort
US6331286B1 (en) * 1998-12-21 2001-12-18 Photogen, Inc. Methods for high energy phototherapeutics
WO1998025892A1 (en) 1996-12-09 1998-06-18 Eli Lilly And Company Integrin antagonists
ES2239801T3 (es) 1997-04-02 2005-10-01 The Brigham And Women's Hospital, Inc. Uso de un agente para disminuir el riesgo de enfermedad cardiovascular.
DE19757250A1 (de) 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
DE60034779T2 (de) 1999-03-15 2008-01-17 Mayo Foundation For Medical Education And Research, Rochester Insulinartiger-wachstumsfaktorbindungsprotein-4-protease
US7115382B1 (en) * 1999-03-15 2006-10-03 Mayo Foundation For Medical Education And Research Method for detecting IGFBP-4 protease without detecting IGFBP-4 protease/proMBP Complex
US6500630B2 (en) * 2001-01-12 2002-12-31 Mayo Foundation For Medical Education And Research Marker for inflammatory conditions
JP4251617B2 (ja) 2003-03-10 2009-04-08 キヤノン株式会社 電子機器
US20060063162A1 (en) * 2004-09-23 2006-03-23 Deng David X Biological marker for inflammation

Also Published As

Publication number Publication date
JP5226749B2 (ja) 2013-07-03
JP2004531696A (ja) 2004-10-14
CA2434512C (en) 2010-05-11
US20060110773A1 (en) 2006-05-25
US20070065879A1 (en) 2007-03-22
US7939280B2 (en) 2011-05-10
US8323913B2 (en) 2012-12-04
US20110212024A1 (en) 2011-09-01
JP2010281833A (ja) 2010-12-16
US20030003521A1 (en) 2003-01-02
WO2002056015A1 (en) 2002-07-18
EP1350109A1 (en) 2003-10-08
DE60232303D1 (de) 2009-06-25
US6699675B2 (en) 2004-03-02
US20100285510A1 (en) 2010-11-11
DK1350109T3 (da) 2009-08-31
EP1350109A4 (en) 2004-08-18
ES2324767T3 (es) 2009-08-14
US20040197844A1 (en) 2004-10-07
US7723049B2 (en) 2010-05-25
EP1350109B1 (en) 2009-05-13
US20090197342A1 (en) 2009-08-06
ATE431551T1 (de) 2009-05-15
US20020132278A1 (en) 2002-09-19
JP4610660B2 (ja) 2011-01-12
JP2009198510A (ja) 2009-09-03
EP2081026A1 (en) 2009-07-22
AU2002241845B2 (en) 2006-11-09
US6500630B2 (en) 2002-12-31
US20050136498A1 (en) 2005-06-23
CA2434512A1 (en) 2002-07-18
JP4338972B2 (ja) 2009-10-07

Similar Documents

Publication Publication Date Title
PT1350109E (pt) Marcador para patologias inflamatórias
AU2002213461A1 (en) Linear power amplifier bias circuit
AU2002220241A1 (en) Parb inhibitors
AU2002248553A1 (en) Linear y-carboxyglutamate rich conotoxins
IL143993A0 (en) An incineration process using high oxygen concentrations
AU2002244110A1 (en) Distributed amplifier with transistors having negative feedback
AU2001226390A1 (en) Uv curable ferromagnetic compositions
TW514015U (en) Carpentry lathe
GB2363676B (en) Plasma source
AU2002349621A1 (en) Angiogenesis inhibitor
AU2002360673A1 (en) Gp41 inhibitor
AU2001283340A1 (en) Factor viia inhibitors
IL158640A0 (en) Agents for reducing atmospheric oxidising pollutants
AU2002218636A1 (en) Hardening fixture
AU2003205994A1 (en) Worktable
WO2003031574A3 (en) Elastase inhibitors
AU2002348869A1 (en) Integrated circuit with an amplifier
AU2001236708A1 (en) Circuits with dynamic biasing
GB0125961D0 (en) Electron source and electron column
AU2002324708A1 (en) Wafer chuck with plunger
AU2002350002A1 (en) Suppository base
AU2002314504A1 (en) An incineration process using high oxygen concentrations
AU2002238815A1 (en) Device for the partial annealing of machined mechanical parts
JO2233B1 (en) Dew solar tube
AU2002238022A1 (en) Linear tensioner